Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, today announced initiation of a new clinical trial designed to evaluate the safety and efficacy of its tumor necrosis therapy (TNT) agent Cotara(R) in patients with glioblastoma multiforme (GBM), a deadly...
Peregrine Pharmaceuticals Reports Positive Top-Line Results in
Bavituximab Combination Therapy Trial in Advanced Cancer Patients
- 50% of All Evaluable Patients Receiving Combination ofBavituximab Plus Chemotherapy Achieved ObjectiveTumor Response or Stable Disease - - 75% of Patients Receiving Combination ofBavituximab Plus Gemcitabine Achieved Objective Tumor Response or Stable Disease - - 50% ofPatients Receiving Combination of Bavituximab Plus...
Positive Results Using Affitech-Identified Human Antibody That
Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model
Reported by Peregrine
OSLO, Norway--(BUSINESS WIRE)--Apr 23, 2007 - Affitech AS, thehuman antibody therapeutics company announced today that
PeregrinePharmaceuticals, Inc. reported positive in vivo test results of R3,a fully human monoclonal antibody developed by Affitech, in apancreatic cancer model at the recently concluded Centennial AnnualMeeting of the American Association for Cancer Research (AACR). R3has...
Peregrine Pharmaceuticals Highlights Significant Advances in the
Company's Clinical and Preclinical Cancer Programs Presented This
Week at the AACR Annual Meeting
- New Study Demonstrated the Clinical Potential of
Peregrine'sUnique Selective Anti-VEGF Antibodies, Which Were as Effective asAvastin(R) in Animal Cancer Models TUSTIN, Calif., April 20, 2007 /PRNewswire-FirstCall/ --
Peregrine Pharmaceuticals, Inc. , a clinical stagebiopharmaceutical company developing targeted monoclonal antibodiesfor the treatment of cancer and hepatitis C virus infect...
Data Presented at AACR Meeting Shows Peregrine's Immunocytokine
Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in
Preclinical Studies
- New Studies Confirm That Fusion Proteins Made by CombiningCytokines With
Peregrine's Anti-PS Antibodies Demonstrate IncreasedAnti-Tumor Activity With No Observable Toxicity - LOS ANGELES and TUSTIN, Calif., April 18, 2007/PRNewswire-FirstCall/ --
Peregrine Pharmaceuticals, Inc. , aclinical stage biopharmaceutical company developing targetedmonoclonal antibodies for the treatment of canc...
Data Presented at AACR Meeting Show Peregrine's Bavituximab
Equivalent Can Generate Curative Immune Responses as Part of a
Vaccine-Like Regimen in Preclinical Models of Aggressive Brain
Cancer
--Immunization with a Bavituximab Equivalent and Irradiated TumorCells Increased Long-Term Survival to 57% From 0% in Controls in aPreclinical Model of Brain Cancer-- LOS ANGELES and TUSTIN, Calif., April 18, 2007/PRNewswire-FirstCall/ --
Peregrine Pharmaceuticals, Inc. , aclinical stage biopharmaceutical company developing targetedmonoclonal antibodies for the treatment of cancer and hep...
More>>